Q3-osavuosiraportti
14 päivää sitten‧28 min
Tarjoustasot
First North Sweden
Määrä
Osto
300
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 000 | 15 000 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 000 | 15 000 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Ylimääräinen yhtiökokous | 27.10. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2024 Yhtiökokous | 15.5. | |
| 2025 Q1-osavuosiraportti | 12.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenAfter reviewing the latest information, incl. calculations, statements from Acarix, new studies, reimbursement data and the RHT program in the USA, some things stand out clearly: 1. The American consignment model Acarix confirms that the target for each new clinic in the USA is approximately 13 boxes the first year and then at least one box per month. A box contains 20 patches, and the average price is around 464 kr. The patch margin is very high (85–90 %), which means that patch consumption is the part of the business that provides the largest and most stable earnings. With the 22 new consignment systems in the USA per quarter, this already provides solid revenue growth. 2. Studies and economic effect New analyses – including from SpringerLink – show that CADScor is significantly more cost-effective than many other diagnostic tests. This means that American clinics save money by using CADScor. This increases the likelihood of further reimbursement agreements and dissemination in emergency departments and primary care. 3. The RHT program in the USA (50 bn. USD) Applications for 2026-2030 have been submitted, and the decision will come on December 31, 2025. Acarix fits directly into the program's purpose: early diagnostics, AI, remote diagnostics, and reduction of unnecessary hospital costs. If Acarix or their partners become part of the RHT rollout, it could mean a very large number of installations over the coming years. 4. Market activity in the USA There is high activity: more doctors and organizations are making contact, and both CADScor and Seismo are being received positively. In addition, Acarix has gained strong profiles in the board and management, which strengthens credibility and network. 5. Timeline – RHT response: December 31, 2025 – Payments start from January and continue into Q2 2026 – The consignment model grows quarter by quarter – Patch sales follow suit and constitute the largest part of future earnings Overall assessment All signs indicate that 2026 will be a decisive year for Acarix. The combination of increasing patch consumption, a growing consignment network in the USA, strong studies, and a possible breakthrough via the RHT program creates a solid foundation for growth. It is still a high-risk stock, but based on current data, the company stands significantly stronger than before, both commercially and strategically
·13.11.How long should one stay seated here, before it just just goes up a little ….
·2 päivää sitten- 19% here and have been here for 1.5 years, I am not ready to abandon ship at the moment, I am sure my patience will be tested, but if it holds, then I also think it will pay off :-)
·9.11. · MuokattuRHT is a real dark horse right now that can truly become a total game changer for Acarix. The good thing is, as you know, that the application is already complete and an answer is expected by the end of December. Some clipped quotes from the website with information about RHT: "Spark the growth of innovative care models to improve health outcomes" "Foster use of innovative technologies that promote efficient care delivery" "Developing projects that support innovative models of care that include value-based care arrangements" This really fits perfectly with CadScore, which can offer economic & affordable diagnostics specifically for rural areas with lower budgets where cardiologists are often lacking, etc. Quote Aamir: "Fitting to the T, we are the definition of what they are trying to do". I can only agree, it doesn't feel like a long shot but rather that it couldn't be stranger if Acarix doesn't get a piece of that $50 billion pie, which, as mentioned, would truly be perfect timing now that things are really starting to look promising. This, which is just one possibility, combined with Aamir's drive... the stock is ridiculously undervalued!? Perhaps it's not so strange that it has taken a long time to get here, but history has little to do with the future as it looks now.·1 päivä sittenRegardless of the outcome, it's nice that there won't be a long wait for a decision, only one application for the entire 5-year period and the application deadline has already passed, as is known... Google-AI om RHT: It is highly likely that Acarix will seek funding for its CADScor system through the Rural Health Transformation Program, and it has a strong chance of success because it is a technology-based solution that can help meet the program's goals of improving rural healthcare access and technology. Recent news shows the company has secured fixed U.S. reimbursement from some payers, which will likely strengthen its applications, and a significant portion of the program's funding is dedicated to improving rural healthcare through technology. Factors supporting Acarix's success - Alignment with program goals: The Rural Health Transformation Program aims to improve rural healthcare delivery through technology. Acarix's CADScor system is an innovative, AI- and acoustics-based diagnostic tool that can improve access to cardiac diagnostics, a critical need in rural areas. - Demonstrated success: Acarix has already demonstrated the potential of its system to provide cost-effective and high-quality care, which will likely strengthen its funding applications. - Established reimbursement: The company has secured fixed reimbursement from several U.S. payers, which is a significant milestone that removes a major barrier to adoption. This reimbursement will likely be a key factor in securing funding for the Rural Health Transformation Program. - Growing demand for technology: The program is designed to fund states that can demonstrate how they will use technology to improve healthcare delivery, which aligns with the CADScor system's technology-driven approach.- ·7.11. · MuokattuHas RHS, which Aamir talks a lot about in the presentation, been discussed here yet? Talk about it fitting Acarix 100% Rural Health Transformation refers to a federal program to revitalize rural healthcare through a $50 billion investment authorized by the One Big Beautiful Bill Act. The program aims to strengthen rural health infrastructure by funding state-designed plans that focus on strategic goals such as improving access to care, developing the healthcare workforce, promoting innovation and preventative health, and expanding technology. States submitted applications to the Centers for Medicare & Medicaid Services (CMS) for funding, with the application period closing on November 5, 2025. Awards are expected to be announced by December 31, 2025.
- ·6.11. · MuokattuAamir works extremely hard with 100% commitment and seems to be doing most things right, while also being heavily invested in the company himself. If it continues in the right direction at this pace, this will turn out really well quite soon. With halved cash burn and increasing revenues, liquid funds will last until mid-2026, and just as Aamir says, this ensures that potential new financing can be arranged then with good terms. The Rural Health Grant also sounds clearly interesting and is truly a perfect match for Casdscore. I find it hard to understand today's mild reaction!
·7.11. · MuokattuI have three points: 1) The Q2 report was probably not very good - at least not financially. Many investors may be concerned that the Q3 figures are a one-off driven by MENA sales, and will want to see more consistency before they truly enter the case. 2) Concerns about further dilution in 2026 and/or new costs related to the new innovations Acarix is working on. 3) Financial reports are pouring out these days - including major market fluctuations. Acarix is probably not a top priority in many places, so maybe things just need to settle down? I can certainly say yes to all three points - I just need to figure out if now is the time to put more money into Acarix.·7.11.1. Nothing says that MENA cannot increase both in the short and long term. 22 new CS in the USA in just one quarter is certainly not to be underestimated. 2. There are currently approximately 21 MSEK in liquid assets. With a cash burn of 2.5-3 MSEK / month, that's enough well into 2026. And if revenues continue to increase on top of that... 3. True, it would be sensible with some AI-Tech bubble money transferred to neglected MedTech now!! Overall, Aamir is really holding onto the money while doing most things right!! It is undoubtedly moving in the right direction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
14 päivää sitten‧28 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenAfter reviewing the latest information, incl. calculations, statements from Acarix, new studies, reimbursement data and the RHT program in the USA, some things stand out clearly: 1. The American consignment model Acarix confirms that the target for each new clinic in the USA is approximately 13 boxes the first year and then at least one box per month. A box contains 20 patches, and the average price is around 464 kr. The patch margin is very high (85–90 %), which means that patch consumption is the part of the business that provides the largest and most stable earnings. With the 22 new consignment systems in the USA per quarter, this already provides solid revenue growth. 2. Studies and economic effect New analyses – including from SpringerLink – show that CADScor is significantly more cost-effective than many other diagnostic tests. This means that American clinics save money by using CADScor. This increases the likelihood of further reimbursement agreements and dissemination in emergency departments and primary care. 3. The RHT program in the USA (50 bn. USD) Applications for 2026-2030 have been submitted, and the decision will come on December 31, 2025. Acarix fits directly into the program's purpose: early diagnostics, AI, remote diagnostics, and reduction of unnecessary hospital costs. If Acarix or their partners become part of the RHT rollout, it could mean a very large number of installations over the coming years. 4. Market activity in the USA There is high activity: more doctors and organizations are making contact, and both CADScor and Seismo are being received positively. In addition, Acarix has gained strong profiles in the board and management, which strengthens credibility and network. 5. Timeline – RHT response: December 31, 2025 – Payments start from January and continue into Q2 2026 – The consignment model grows quarter by quarter – Patch sales follow suit and constitute the largest part of future earnings Overall assessment All signs indicate that 2026 will be a decisive year for Acarix. The combination of increasing patch consumption, a growing consignment network in the USA, strong studies, and a possible breakthrough via the RHT program creates a solid foundation for growth. It is still a high-risk stock, but based on current data, the company stands significantly stronger than before, both commercially and strategically
- ·13.11.How long should one stay seated here, before it just just goes up a little ….·2 päivää sitten- 19% here and have been here for 1.5 years, I am not ready to abandon ship at the moment, I am sure my patience will be tested, but if it holds, then I also think it will pay off :-)
- ·9.11. · MuokattuRHT is a real dark horse right now that can truly become a total game changer for Acarix. The good thing is, as you know, that the application is already complete and an answer is expected by the end of December. Some clipped quotes from the website with information about RHT: "Spark the growth of innovative care models to improve health outcomes" "Foster use of innovative technologies that promote efficient care delivery" "Developing projects that support innovative models of care that include value-based care arrangements" This really fits perfectly with CadScore, which can offer economic & affordable diagnostics specifically for rural areas with lower budgets where cardiologists are often lacking, etc. Quote Aamir: "Fitting to the T, we are the definition of what they are trying to do". I can only agree, it doesn't feel like a long shot but rather that it couldn't be stranger if Acarix doesn't get a piece of that $50 billion pie, which, as mentioned, would truly be perfect timing now that things are really starting to look promising. This, which is just one possibility, combined with Aamir's drive... the stock is ridiculously undervalued!? Perhaps it's not so strange that it has taken a long time to get here, but history has little to do with the future as it looks now.·1 päivä sittenRegardless of the outcome, it's nice that there won't be a long wait for a decision, only one application for the entire 5-year period and the application deadline has already passed, as is known... Google-AI om RHT: It is highly likely that Acarix will seek funding for its CADScor system through the Rural Health Transformation Program, and it has a strong chance of success because it is a technology-based solution that can help meet the program's goals of improving rural healthcare access and technology. Recent news shows the company has secured fixed U.S. reimbursement from some payers, which will likely strengthen its applications, and a significant portion of the program's funding is dedicated to improving rural healthcare through technology. Factors supporting Acarix's success - Alignment with program goals: The Rural Health Transformation Program aims to improve rural healthcare delivery through technology. Acarix's CADScor system is an innovative, AI- and acoustics-based diagnostic tool that can improve access to cardiac diagnostics, a critical need in rural areas. - Demonstrated success: Acarix has already demonstrated the potential of its system to provide cost-effective and high-quality care, which will likely strengthen its funding applications. - Established reimbursement: The company has secured fixed reimbursement from several U.S. payers, which is a significant milestone that removes a major barrier to adoption. This reimbursement will likely be a key factor in securing funding for the Rural Health Transformation Program. - Growing demand for technology: The program is designed to fund states that can demonstrate how they will use technology to improve healthcare delivery, which aligns with the CADScor system's technology-driven approach.
- ·7.11. · MuokattuHas RHS, which Aamir talks a lot about in the presentation, been discussed here yet? Talk about it fitting Acarix 100% Rural Health Transformation refers to a federal program to revitalize rural healthcare through a $50 billion investment authorized by the One Big Beautiful Bill Act. The program aims to strengthen rural health infrastructure by funding state-designed plans that focus on strategic goals such as improving access to care, developing the healthcare workforce, promoting innovation and preventative health, and expanding technology. States submitted applications to the Centers for Medicare & Medicaid Services (CMS) for funding, with the application period closing on November 5, 2025. Awards are expected to be announced by December 31, 2025.
- ·6.11. · MuokattuAamir works extremely hard with 100% commitment and seems to be doing most things right, while also being heavily invested in the company himself. If it continues in the right direction at this pace, this will turn out really well quite soon. With halved cash burn and increasing revenues, liquid funds will last until mid-2026, and just as Aamir says, this ensures that potential new financing can be arranged then with good terms. The Rural Health Grant also sounds clearly interesting and is truly a perfect match for Casdscore. I find it hard to understand today's mild reaction!·7.11. · MuokattuI have three points: 1) The Q2 report was probably not very good - at least not financially. Many investors may be concerned that the Q3 figures are a one-off driven by MENA sales, and will want to see more consistency before they truly enter the case. 2) Concerns about further dilution in 2026 and/or new costs related to the new innovations Acarix is working on. 3) Financial reports are pouring out these days - including major market fluctuations. Acarix is probably not a top priority in many places, so maybe things just need to settle down? I can certainly say yes to all three points - I just need to figure out if now is the time to put more money into Acarix.·7.11.1. Nothing says that MENA cannot increase both in the short and long term. 22 new CS in the USA in just one quarter is certainly not to be underestimated. 2. There are currently approximately 21 MSEK in liquid assets. With a cash burn of 2.5-3 MSEK / month, that's enough well into 2026. And if revenues continue to increase on top of that... 3. True, it would be sensible with some AI-Tech bubble money transferred to neglected MedTech now!! Overall, Aamir is really holding onto the money while doing most things right!! It is undoubtedly moving in the right direction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
300
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 000 | 15 000 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 000 | 15 000 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Ylimääräinen yhtiökokous | 27.10. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2024 Yhtiökokous | 15.5. | |
| 2025 Q1-osavuosiraportti | 12.5. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
14 päivää sitten‧28 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Ylimääräinen yhtiökokous | 27.10. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2024 Yhtiökokous | 15.5. | |
| 2025 Q1-osavuosiraportti | 12.5. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenAfter reviewing the latest information, incl. calculations, statements from Acarix, new studies, reimbursement data and the RHT program in the USA, some things stand out clearly: 1. The American consignment model Acarix confirms that the target for each new clinic in the USA is approximately 13 boxes the first year and then at least one box per month. A box contains 20 patches, and the average price is around 464 kr. The patch margin is very high (85–90 %), which means that patch consumption is the part of the business that provides the largest and most stable earnings. With the 22 new consignment systems in the USA per quarter, this already provides solid revenue growth. 2. Studies and economic effect New analyses – including from SpringerLink – show that CADScor is significantly more cost-effective than many other diagnostic tests. This means that American clinics save money by using CADScor. This increases the likelihood of further reimbursement agreements and dissemination in emergency departments and primary care. 3. The RHT program in the USA (50 bn. USD) Applications for 2026-2030 have been submitted, and the decision will come on December 31, 2025. Acarix fits directly into the program's purpose: early diagnostics, AI, remote diagnostics, and reduction of unnecessary hospital costs. If Acarix or their partners become part of the RHT rollout, it could mean a very large number of installations over the coming years. 4. Market activity in the USA There is high activity: more doctors and organizations are making contact, and both CADScor and Seismo are being received positively. In addition, Acarix has gained strong profiles in the board and management, which strengthens credibility and network. 5. Timeline – RHT response: December 31, 2025 – Payments start from January and continue into Q2 2026 – The consignment model grows quarter by quarter – Patch sales follow suit and constitute the largest part of future earnings Overall assessment All signs indicate that 2026 will be a decisive year for Acarix. The combination of increasing patch consumption, a growing consignment network in the USA, strong studies, and a possible breakthrough via the RHT program creates a solid foundation for growth. It is still a high-risk stock, but based on current data, the company stands significantly stronger than before, both commercially and strategically
- ·13.11.How long should one stay seated here, before it just just goes up a little ….·2 päivää sitten- 19% here and have been here for 1.5 years, I am not ready to abandon ship at the moment, I am sure my patience will be tested, but if it holds, then I also think it will pay off :-)
- ·9.11. · MuokattuRHT is a real dark horse right now that can truly become a total game changer for Acarix. The good thing is, as you know, that the application is already complete and an answer is expected by the end of December. Some clipped quotes from the website with information about RHT: "Spark the growth of innovative care models to improve health outcomes" "Foster use of innovative technologies that promote efficient care delivery" "Developing projects that support innovative models of care that include value-based care arrangements" This really fits perfectly with CadScore, which can offer economic & affordable diagnostics specifically for rural areas with lower budgets where cardiologists are often lacking, etc. Quote Aamir: "Fitting to the T, we are the definition of what they are trying to do". I can only agree, it doesn't feel like a long shot but rather that it couldn't be stranger if Acarix doesn't get a piece of that $50 billion pie, which, as mentioned, would truly be perfect timing now that things are really starting to look promising. This, which is just one possibility, combined with Aamir's drive... the stock is ridiculously undervalued!? Perhaps it's not so strange that it has taken a long time to get here, but history has little to do with the future as it looks now.·1 päivä sittenRegardless of the outcome, it's nice that there won't be a long wait for a decision, only one application for the entire 5-year period and the application deadline has already passed, as is known... Google-AI om RHT: It is highly likely that Acarix will seek funding for its CADScor system through the Rural Health Transformation Program, and it has a strong chance of success because it is a technology-based solution that can help meet the program's goals of improving rural healthcare access and technology. Recent news shows the company has secured fixed U.S. reimbursement from some payers, which will likely strengthen its applications, and a significant portion of the program's funding is dedicated to improving rural healthcare through technology. Factors supporting Acarix's success - Alignment with program goals: The Rural Health Transformation Program aims to improve rural healthcare delivery through technology. Acarix's CADScor system is an innovative, AI- and acoustics-based diagnostic tool that can improve access to cardiac diagnostics, a critical need in rural areas. - Demonstrated success: Acarix has already demonstrated the potential of its system to provide cost-effective and high-quality care, which will likely strengthen its funding applications. - Established reimbursement: The company has secured fixed reimbursement from several U.S. payers, which is a significant milestone that removes a major barrier to adoption. This reimbursement will likely be a key factor in securing funding for the Rural Health Transformation Program. - Growing demand for technology: The program is designed to fund states that can demonstrate how they will use technology to improve healthcare delivery, which aligns with the CADScor system's technology-driven approach.
- ·7.11. · MuokattuHas RHS, which Aamir talks a lot about in the presentation, been discussed here yet? Talk about it fitting Acarix 100% Rural Health Transformation refers to a federal program to revitalize rural healthcare through a $50 billion investment authorized by the One Big Beautiful Bill Act. The program aims to strengthen rural health infrastructure by funding state-designed plans that focus on strategic goals such as improving access to care, developing the healthcare workforce, promoting innovation and preventative health, and expanding technology. States submitted applications to the Centers for Medicare & Medicaid Services (CMS) for funding, with the application period closing on November 5, 2025. Awards are expected to be announced by December 31, 2025.
- ·6.11. · MuokattuAamir works extremely hard with 100% commitment and seems to be doing most things right, while also being heavily invested in the company himself. If it continues in the right direction at this pace, this will turn out really well quite soon. With halved cash burn and increasing revenues, liquid funds will last until mid-2026, and just as Aamir says, this ensures that potential new financing can be arranged then with good terms. The Rural Health Grant also sounds clearly interesting and is truly a perfect match for Casdscore. I find it hard to understand today's mild reaction!·7.11. · MuokattuI have three points: 1) The Q2 report was probably not very good - at least not financially. Many investors may be concerned that the Q3 figures are a one-off driven by MENA sales, and will want to see more consistency before they truly enter the case. 2) Concerns about further dilution in 2026 and/or new costs related to the new innovations Acarix is working on. 3) Financial reports are pouring out these days - including major market fluctuations. Acarix is probably not a top priority in many places, so maybe things just need to settle down? I can certainly say yes to all three points - I just need to figure out if now is the time to put more money into Acarix.·7.11.1. Nothing says that MENA cannot increase both in the short and long term. 22 new CS in the USA in just one quarter is certainly not to be underestimated. 2. There are currently approximately 21 MSEK in liquid assets. With a cash burn of 2.5-3 MSEK / month, that's enough well into 2026. And if revenues continue to increase on top of that... 3. True, it would be sensible with some AI-Tech bubble money transferred to neglected MedTech now!! Overall, Aamir is really holding onto the money while doing most things right!! It is undoubtedly moving in the right direction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
300
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 000 | 15 000 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 000 | 15 000 | 0 | 0 |